BioCentury | Apr 8, 2021
Product Development

Next-generation drug conjugates in the spotlight at AACR

Next-generation iterations of antibody-drug conjugate constructs are on display at this year’s AACR conference as companies and academic groups work to improve upon — and broaden the capabilities of ...
BioCentury | Apr 1, 2020
Finance

March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi

AM-Pharma raises $52M series C extension AM-Pharma B.V. raised €47 million ($51.7 million) in an additional close of its series C round, bringing the total funds raised in the round to €163 million. The round...
BioCentury | Jan 29, 2020
Company News

Launches fuel Novartis’ growth as CEO reiterates China commitment

With over 90% commercial payer coverage for SMA gene therapy Zolgensma and increased uptake for heart failure drug Entresto, Novartis posted nearly double-digit sales growth in 2019 as the pharma looks to additional new drugs...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | May 28, 2019
Company News

Months after scuttling IPO bid, Centrexion adds to balance sheet with Lilly deal for pain therapy

...eligible for $950 million in milestones. The deal gives Eli Lilly and Co. (NYSE:LLY) oral SSTR4...
...Nerve growth factor; PACAP38 - Pituitary adenylate cyclase activating polypeptide-38 isoform; SSTR4 - Small molecule somatostatin receptor 4...
...VR1) - Transient receptor potential vanilloid 1 Mark Zipkin, Staff Writer CNTX-0290 Centrexion Therapeutics Corp. Eli Lilly and Co. Somatostatin receptor 4 (SSTR4) Pain...
BioCentury | Feb 21, 2019
Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
BioCentury | Feb 20, 2019
Clinical News

Partial hold for Phase I of Xencor's blood cancer bispecific

Xencor Inc. (NASDAQ:XNCR) said FDA placed a partial clinical hold on a Phase I trial of XmAb14045 following two patient deaths that were considered possibly related to treatment with the bispecific antibody against CD3 and...
BioCentury | Jan 3, 2019
Financial News

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

Tiburio Therapeutics Inc. (Cambridge, Mass.) launched Thursday with a $31 million series A round and two clinical compounds licensed from Ipsen Group (Euronext:IPN; Pink:IPSEY) that it plans to develop for rare neuroendocrine tumors and rare...
BioCentury | Sep 28, 2018
Clinical News

Innovent's PD-1 Inhibitor leads to 22.7% ORR in Phase Ib for NETs

Innovent Biologics Inc. (Suzhou, China) said anti-PD-1 antibody sintilimab (IBI308) led to an objective response rate (ORR) of 22.7% in 22 evaluable patients with neuroendocrine tumors (NETs) who failed standard therapy in a Chinese Phase...
BioCentury | Sep 21, 2018
Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...
Items per page:
1 - 10 of 136